RecruitingPhase 4

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

France1,800 participantsStarted 2025-04-18

Plain-language summary

Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eligible for anti-chikungunya vaccination according to french Health Authority (HAS) * Beneficiary of social security coverage * Signature of informed consent form Exclusion Criteria: * Pregnant women * Vaccine contraindication for patients undergoing medical treatment * Persons under guardianship, curatorship or safeguard of justice * Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration

What they're measuring

To measure the vaccine effectiveness at 6 months

Timeframe: 6 months

Trial details

NCT IDNCT06928753

SponsorCentre Hospitalier Universitaire de la Réunion

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04

Contact for this trial

Patrick GERARDIN, MD

(262) 2 62 35 9435 patrick.gerardin@chu-reunion.fr

View on ClinicalTrials.gov More Chikungunya Virus Infection trials